CytoSorbents Corporation (CTSO)

[hemopure36]

As usual, you misunderstood (distorted?) what I'm saying. I think the unrealistic part is to assume no FDA Ticagrelor trial as your baseline case. Until one astute poster here pointed out that Dr. Chan said, "...if..." we need a trial, everyone assumed, and by all odds rightly so, that we would be required to conduct one. And we even discussed here that the good news is that the trial would likely be easy and relatively fast. But because Dr. Chan uttered the word, "if," you now try to make people think that if we're required to to a study, it's part of a "we're screwed" scenario, which is very disingenuous, at best. Aside from that, separate and distinct, I think it's a high hill to climb to demonstrate a statistically significant mortality benefit among the REMOVE study cohort. I'm not saying it's impossible, but I think it's rather unlikely. Nonetheless, I do believe that overall, the study will be a success on other endpoints, but I'm sure you will spin it as disastrous, regardless of the outcome. I don't know how you can routinely spin normal, baseline and even good news into an abyss of negativity. It's just astounding to me and I hope people who pass by here take it with a grain of salt. Good luck!